(Editors' Note: Stallergenes trades on the Paris Stock Exchange under the ticker symbol GENP.PA, with €300K average daily volume).
With about 27% share of the $1.2 billion immunotherapy market, French biotech Stallergenes (OTCPK:STLEF) is one of the two world market leaders in the field of desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, such as rhinoconjunctivitis, rhinitis and allergic asthma. Stallergenes is present in almost 40 countries via ten subsidiaries in Europe in Germany, Italy, Spain, Belgium, Switzerland, the Netherlands, the Czech Republic, Slovakia, Austria and Great Britain, and has entered into numerous partnerships and distribution agreements. Stallergenes has recently accelerated its global expansion by offering Oralair, the first ever immunotherapy tablet...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|